Extract

This was an 18-month, multi-center, open-label, clinical extension study. Patients completing earlier second extension studies (CACZ885H2356E2 and CACZ885H2357E2) continued to be treated in this combined extension 3 study for any new gouty arthritis flare on demand with one subcutaneous (s.c.) injection of canakinumab 150 mg.

Inclusion criteria

• Acute Gouty Arthritis Flares

Country

• Australia
• Canada
• Estonia
• Germany
• Latvia
• Lithuania
• Russian Federation
• Ukraine
• United States

Links

• nct
• ictrp